Journal of Clinical Medicine (Jul 2021)

Effects of Childhood Multidisciplinary Care and Growth Hormone Treatment on Health Problems in Adults with Prader-Willi Syndrome

  • Karlijn Pellikaan,
  • Anna G. W. Rosenberg,
  • Kirsten Davidse,
  • Anja A. Kattentidt-Mouravieva,
  • Rogier Kersseboom,
  • Anja G. Bos-Roubos,
  • Lionne N. Grootjen,
  • Layla Damen,
  • Sjoerd A. A. van den Berg,
  • Aart J. van der Lely,
  • Anita C. S. Hokken-Koelega,
  • Laura C. G. de Graaff

DOI
https://doi.org/10.3390/jcm10153250
Journal volume & issue
Vol. 10, no. 15
p. 3250

Abstract

Read online

Prader-Willi syndrome (PWS) is a complex hypothalamic disorder. Features of PWS include hyperphagia, hypotonia, intellectual disability, and pituitary hormone deficiencies. The combination of growth hormone treatment and multidisciplinary care (GHMDc) has greatly improved the health of children with PWS. Little is known about the effects of childhood GHMDc on health outcomes in adulthood. We retrospectively collected clinical data of 109 adults with PWS. Thirty-nine had received GHMDc during childhood and adolescence (GHMDc+ group) and sixty-three had never received growth hormone treatment (GHt) nor multidisciplinary care (GHMDc− group). Our systematic screening revealed fewer undetected health problems in the GHMDc+ group (10%) than in the GHMDc− group (84%). All health problems revealed in the GHMDc+ group had developed between the last visit to the paediatric and the first visit to the adult clinic and/or did not require treatment. Mean BMI and the prevalence of diabetes mellitus type 2 were significantly lower in the GHMDc+ group compared to the GHMDc− group. As all patients who received GHt were treated in a multidisciplinary setting, it is unknown which effects are the result of GHt and which are the result of multidisciplinary care. However, our data clearly show that the combination of both has beneficial effects. Therefore, we recommend continuing GHMDc after patients with PWS have reached adult age.

Keywords